A La CaRT: Australasian Laparoscopic Cancer Of The Rectum Trial. A Phase III Prospective Randomised Trial Comparing Laparoscopic-assisted Resection Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$599,054.00
Summary
The major treatment for rectal cancer is surgical removal of tumour with a large cut through the abdomen. There is a newer, less invasive procedure known as laparoscopic resection which enables the same surgery to be performed using a scope inserted in the abdomen and another smaller incision for removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure. Patients on the trial will be given either laparoscopi
A La CaRT: Australasian Phase III Randomised Trial Comparing Laparoscopic-assisted Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$974,440.00
Summary
The current major treatment for rectal cancer is surgical removal of the cancer. This type of surgery requires a large cut through the abdomen for removal of the cancer. There is a newer, less invasive procedure known as laparoscopic resection enabling the same surgery by using a scope inserted in the abdomen along with a smaller incision to allow removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure.
Childhood Lymphatic Malformations: The Mechanism Of Rapamycin In Controlling Growth
Funder
National Health and Medical Research Council
Funding Amount
$456,579.00
Summary
Lymphatic malformations (also known as cystic hygromas or lymphangiomas) cause deformity and pain which can last lifelong. Current treatments help but do not fix all the symptoms. Rapamycin, a drug used for many years in children and adults with kidney transplants, may be useful for treating children with lymphatic malformations. We aim to understand how the drug works on the cells of lymphatic malformations in culture and in an animal model, to develop new and more effective treatments.
Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.